Clinical safety and efficacy of NG440: a novel combination of rho iso-alpha acids from hops, rosemary, and oleanolic acid for inflammatory conditionsThis article is one of a selection of papers published in this special issue (part 1 of 2) on the Safety and Efficacy of Natural Health Products.
- 1 September 2007
- journal article
- clinical trial
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 85 (9) , 872-883
Abstract
In this report, we examine the clinical safety and efficacy of NG440, a phytochemical-based antiinflammatory formula consisting of a combination of rho iso-alpha acids from hops, rosemary, and oleanolic acid. In a previous study, we demonstrated that NG440 significantly decreased pain by 50% in patients with osteoarthritis. Consistent with these data, results from a multicentre trial indicate that NG440 reduced pain scores in patients with joint discomfort, as measured by VAS (visual analog scale) methodology. As demonstrated in an ex vivo clinical study, these effects on pain relief may be due to reduced inflammatory cytokine production including lower prostaglandin E2formation. Finally, strong data exist to suggest that NG440 is a safe formula for human consumption. Animal toxicity data revealed no adverse effects of NG440 at dosages ≤250 mg·kg–1·day–1for 21 days. Furthermore, human trial data suggest that NG440 does not negatively impact cardiovascular and gastrointestinal markers normally affected by selective COX-2 enzyme inhibitors, including platelet function, blood pressure, blood cell count, or fecal calprotectin, a measure of gastrointestinal injury. In conclusion, NG440 may serve as a safe and efficacious alternative in some areas where specific COX-2 inhibitors have been traditionally used.Keywords
This publication has 35 references indexed in Scilit:
- Is non-steroidal anti-inflammaory drug (NSAID) enteropathy clinically more important than NSAID gastropathy?Postgraduate Medical Journal, 2006
- Selective COX-2 inhibitors and risk of thromboembolic events – regulatory aspectsThrombosis and Haemostasis, 2006
- A Pilot trial evaluating meta050, a proprietary combination of reduced iso-alpha acids, rosemary extract and oleanolic acid in patients with arthritis and fibromyalgiaPhytotherapy Research, 2005
- Effect of COX-1/COX-2 Inhibition versus Selective COX-2 Inhibition on Coronary Vasodilator Responses to Arachidonic Acid and AcetylcholinePharmacology, 2004
- Cyclooxygenases: new forms, new inhibitors, and lessons from the clinicThe FASEB Journal, 2004
- Cyclooxygenases, the Kidney, and HypertensionHypertension, 2004
- The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial diseasePlatelets, 2004
- NSAIDs: the Emperor’s new dogma?Gut, 2003
- High prevalence of NSAID enteropathy as shown by a simple faecal testGut, 1999
- Faecal Calprotectin Shedding after Short-Term Treatment with Non-Steroidal Anti-Inflammatory DrugsScandinavian Journal of Gastroenterology, 1996